Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial.

Ebrahimi F, Urwyler SA, Schuetz P, Mueller B, Bernasconi L, Neyer P, Donath MY, Christ-Crain M.

Endocr Connect. 2019 Jun 1;8(6):701-708. doi: 10.1530/EC-19-0201.

2.

Cytokines and Cortisol - predictors of treatment response to corticosteroids in community-acquired pneumonia?

Urwyler SA, Blum CA, Coslovsky M, Mueller B, Schuetz P, Christ-Crain M.

J Intern Med. 2019 Jul;286(1):75-87. doi: 10.1111/joim.12891. Epub 2019 Mar 14.

PMID:
30873676
3.

Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial.

Blum CA, Schuetz P, Nigro N, Winzeler B, Arici B, Refardt J, Urwyler SA, Rodondi N, Blum MR, Briel M, Mueller B, Christ-Crain M.

Clin Endocrinol (Oxf). 2019 Sep;91(3):374-382. doi: 10.1111/cen.13907. Epub 2019 Jan 9.

PMID:
30485501
4.

IL-1 Antagonism in Men With Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial.

Ebrahimi F, Urwyler SA, Straumann S, Doerpfeld S, Bernasconi L, Neyer P, Schuetz P, Mueller B, Donath MY, Christ-Crain M.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3466-3476. doi: 10.1210/jc.2018-00739.

PMID:
29939279
5.

Copeptin levels and commonly used laboratory parameters in hospitalised patients with severe hypernatraemia - the "Co-MED study".

Nigro N, Winzeler B, Suter-Widmer I, Schuetz P, Arici B, Bally M, Refardt J, Betz M, Gashi G, Urwyler SA, Burget L, Blum CA, Bock A, Huber A, Müller B, Christ-Crain M.

Crit Care. 2018 Feb 9;22(1):33. doi: 10.1186/s13054-018-1955-7.

6.

Comparison of 1 mg versus 2 mg Dexamethasone Suppression Test in Patients with Obesity.

Urwyler SA, Cupa N, Christ-Crain M.

Horm Metab Res. 2017 Nov;49(11):854-859. doi: 10.1055/s-0043-119128. Epub 2017 Sep 29.

PMID:
28962047
7.

Characterizing bacterial communities in paper production-troublemakers revealed.

Zumsteg A, Urwyler SK, Glaubitz J.

Microbiologyopen. 2017 Aug;6(4). doi: 10.1002/mbo3.487. Epub 2017 May 14.

8.

Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals.

Urwyler SA, Schuetz P, Ebrahimi F, Donath MY, Christ-Crain M.

J Clin Endocrinol Metab. 2017 May 1;102(5):1712-1718. doi: 10.1210/jc.2016-3931.

PMID:
28324042
9.

Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist.

Orain D, Tasdelen E, Haessig S, Koller M, Picard A, Dubois C, Lingenhoehl K, Desrayaud S, Floersheim P, Carcache D, Urwyler S, Kallen J, Mattes H.

ChemMedChem. 2017 Feb 3;12(3):197-201. doi: 10.1002/cmdc.201600467. Epub 2016 Nov 15.

PMID:
27863026
10.

Plasma Apelin Concentrations in Patients With Polyuria-Polydipsia Syndrome.

Urwyler SA, Timper K, Fenske W, de Mota N, Blanchard A, Kühn F, Frech N, Arici B, Rutishauser J, Kopp P, Stettler C, Müller B, Katan M, Llorens-Cortes C, Christ-Crain M.

J Clin Endocrinol Metab. 2016 May;101(5):1917-23. doi: 10.1210/jc.2016-1158. Epub 2016 Mar 11.

PMID:
26967692
11.

Advantage of MALDI-TOF-MS over biochemical-based phenotyping for microbial identification illustrated on industrial applications.

Urwyler SK, Glaubitz J.

Lett Appl Microbiol. 2016 Feb;62(2):130-7. doi: 10.1111/lam.12526.

12.

Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.

Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, Winzeler B, Bingisser R, Elsaesser H, Drozdov D, Arici B, Urwyler SA, Refardt J, Tarr P, Wirz S, Thomann R, Baumgartner C, Duplain H, Burki D, Zimmerli W, Rodondi N, Mueller B, Christ-Crain M.

Lancet. 2015 Apr 18;385(9977):1511-8. doi: 10.1016/S0140-6736(14)62447-8. Epub 2015 Jan 19.

PMID:
25608756
13.

Copeptin as a stress marker prior and after a written examination--the CoEXAM study.

Urwyler SA, Schuetz P, Sailer C, Christ-Crain M.

Stress. 2015 Jan;18(1):134-7. doi: 10.3109/10253890.2014.993966. Epub 2015 Jan 8.

PMID:
25472823
14.

Copeptin concentrations during psychological stress: the PsyCo study.

Siegenthaler J, Walti C, Urwyler SA, Schuetz P, Christ-Crain M.

Eur J Endocrinol. 2014 Dec;171(6):737-42. doi: 10.1530/EJE-14-0405. Epub 2014 Sep 23.

PMID:
25249697
15.

6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists.

Orain D, Ofner S, Koller M, Carcache DA, Froestl W, Allgeier H, Rasetti V, Nozulak J, Mattes H, Soldermann N, Floersheim P, Desrayaud S, Kallen J, Lingenhoehl K, Urwyler S.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):996-9. doi: 10.1016/j.bmcl.2011.12.009. Epub 2011 Dec 8.

PMID:
22197388
16.

Quinazolinedione sulfonamides: a novel class of competitive AMPA receptor antagonists with oral activity.

Koller M, Lingenhoehl K, Schmutz M, Vranesic IT, Kallen J, Auberson YP, Carcache DA, Mattes H, Ofner S, Orain D, Urwyler S.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3358-61. doi: 10.1016/j.bmcl.2011.04.017. Epub 2011 Apr 8.

PMID:
21531559
17.

Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives.

Urwyler S.

Pharmacol Rev. 2011 Mar;63(1):59-126. doi: 10.1124/pr.109.002501. Epub 2011 Jan 12. Review.

PMID:
21228259
18.

Novel N-methyl-D-aspartate receptor antagonists: a review of compounds patented since 2006.

Koller M, Urwyler S.

Expert Opin Ther Pat. 2010 Dec;20(12):1683-702. doi: 10.1517/13543776.2010.533656. Epub 2010 Nov 8. Review.

PMID:
21054234
19.

Prognostic value of copeptin: one-year outcome in patients with acute stroke.

Urwyler SA, Schuetz P, Fluri F, Morgenthaler NG, Zweifel C, Bergmann A, Bingisser R, Kappos L, Steck A, Engelter S, Müller B, Christ-Crain M, Katan M.

Stroke. 2010 Jul;41(7):1564-7. doi: 10.1161/STROKEAHA.110.584649. Epub 2010 May 27.

PMID:
20508186
20.

Isolation of Legionella-containing vacuoles by immuno-magnetic separation.

Urwyler S, Finsel I, Ragaz C, Hilbi H.

Curr Protoc Cell Biol. 2010 Mar;Chapter 3:Unit 3.34. doi: 10.1002/0471143030.cb0334s46.

PMID:
20235103
21.

Endosomal and secretory markers of the Legionella-containing vacuole.

Urwyler S, Brombacher E, Hilbi H.

Commun Integr Biol. 2009;2(2):107-9.

23.

3-(aminomethyl)piperazine-2,5-dione as a novel NMDA glycine site inhibitor from the chemical universe database GDB.

Nguyen KT, Luethi E, Syed S, Urwyler S, Bertrand S, Bertrand D, Reymond JL.

Bioorg Med Chem Lett. 2009 Jul 15;19(14):3832-5. doi: 10.1016/j.bmcl.2009.04.021. Epub 2009 Apr 10.

PMID:
19394821
24.

Major surface glycoproteins of insect forms of Trypanosoma brucei are not essential for cyclical transmission by tsetse.

Vassella E, Oberle M, Urwyler S, Renggli CK, Studer E, Hemphill A, Fragoso C, Bütikofer P, Brun R, Roditi I.

PLoS One. 2009;4(2):e4493. doi: 10.1371/journal.pone.0004493. Epub 2009 Feb 18.

25.

Changes in the properties of allosteric and orthosteric GABAB receptor ligands after a continuous, desensitizing agonist pretreatment.

Gjoni T, Urwyler S.

Eur J Pharmacol. 2009 Jan 28;603(1-3):37-41. doi: 10.1016/j.ejphar.2008.12.014. Epub 2008 Dec 16.

PMID:
19109945
26.

Rab1 guanine nucleotide exchange factor SidM is a major phosphatidylinositol 4-phosphate-binding effector protein of Legionella pneumophila.

Brombacher E, Urwyler S, Ragaz C, Weber SS, Kami K, Overduin M, Hilbi H.

J Biol Chem. 2009 Feb 20;284(8):4846-56. doi: 10.1074/jbc.M807505200. Epub 2008 Dec 17.

27.

Proteome analysis of Legionella vacuoles purified by magnetic immunoseparation reveals secretory and endosomal GTPases.

Urwyler S, Nyfeler Y, Ragaz C, Lee H, Mueller LN, Aebersold R, Hilbi H.

Traffic. 2009 Jan;10(1):76-87. doi: 10.1111/j.1600-0854.2008.00851.x. Epub 2008 Oct 29.

28.

Discovery of NMDA glycine site inhibitors from the chemical universe database GDB.

Nguyen KT, Syed S, Urwyler S, Bertrand S, Bertrand D, Reymond JL.

ChemMedChem. 2008 Oct;3(10):1520-4. doi: 10.1002/cmdc.200800198. No abstract available.

PMID:
18792895
29.

Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABAB receptor desensitization.

Gjoni T, Urwyler S.

Neuropharmacology. 2008 Dec;55(8):1293-9. doi: 10.1016/j.neuropharm.2008.08.008. Epub 2008 Aug 15.

PMID:
18775443
30.

The Legionella pneumophila phosphatidylinositol-4 phosphate-binding type IV substrate SidC recruits endoplasmic reticulum vesicles to a replication-permissive vacuole.

Ragaz C, Pietsch H, Urwyler S, Tiaden A, Weber SS, Hilbi H.

Cell Microbiol. 2008 Dec;10(12):2416-33. doi: 10.1111/j.1462-5822.2008.01219.x. Epub 2008 Aug 15.

PMID:
18673369
31.

Roles of GABAB receptor subtypes in presynaptic auto- and heteroreceptor function regulating GABA and glutamate release.

Waldmeier PC, Kaupmann K, Urwyler S.

J Neural Transm (Vienna). 2008 Oct;115(10):1401-11. doi: 10.1007/s00702-008-0095-7. Epub 2008 Jul 30.

PMID:
18665320
32.

Environmental predators as models for bacterial pathogenesis.

Hilbi H, Weber SS, Ragaz C, Nyfeler Y, Urwyler S.

Environ Microbiol. 2007 Mar;9(3):563-75. Review.

PMID:
17298357
33.

A family of stage-specific alanine-rich proteins on the surface of epimastigote forms of Trypanosoma brucei.

Urwyler S, Studer E, Renggli CK, Roditi I.

Mol Microbiol. 2007 Jan;63(1):218-28.

34.

ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies.

Hintermann S, Vranesic I, Allgeier H, Brülisauer A, Hoyer D, Lemaire M, Moenius T, Urwyler S, Whitebread S, Gasparini F, Auberson YP.

Bioorg Med Chem. 2007 Jan 15;15(2):903-14. Epub 2006 Oct 21.

PMID:
17110115
35.

The positive allosteric modulator GS39783 enhances GABA(B) receptor-mediated inhibition of cyclic AMP formation in rat striatum in vivo.

Gjoni T, Desrayaud S, Imobersteg S, Urwyler S.

J Neurochem. 2006 Mar;96(5):1416-22. Epub 2006 Jan 25.

36.

Expression of procyclin mRNAs during cyclical transmission of Trypanosoma brucei.

Urwyler S, Vassella E, Van Den Abbeele J, Renggli CK, Blundell P, Barry JD, Roditi I.

PLoS Pathog. 2005 Nov;1(3):e22. Epub 2005 Nov 4.

37.
38.

Role of the N-terminal domains of EP and GPEET procyclins in membrane targeting and the establishment of midgut infections by Trypanosoma brucei.

Liniger M, Urwyler S, Studer E, Oberle M, Renggli CK, Roditi I.

Mol Biochem Parasitol. 2004 Oct;137(2):247-51. No abstract available.

PMID:
15383295
39.

Selected amino acids, dipeptides and arylalkylamine derivatives do not act as allosteric modulators at GABAB receptors.

Urwyler S, Gjoni T, Kaupmann K, Pozza MF, Mosbacher J.

Eur J Pharmacol. 2004 Jan 12;483(2-3):147-53.

PMID:
14729102
40.

N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function.

Urwyler S, Pozza MF, Lingenhoehl K, Mosbacher J, Lampert C, Froestl W, Koller M, Kaupmann K.

J Pharmacol Exp Ther. 2003 Oct;307(1):322-30. Epub 2003 Sep 3.

PMID:
12954816
41.

Survival signaling and selective neuroprotection through glutamatergic transmission.

Bahr BA, Bendiske J, Brown QB, Munirathinam S, Caba E, Rudin M, Urwyler S, Sauter A, Rogers G.

Exp Neurol. 2002 Mar;174(1):37-47.

PMID:
11869032
42.

Design, synthesis and preliminary evaluation of novel 3'-substituted carboxycyclopropylglycines as antagonists at group 2 metabotropic glutamate receptors.

Pellicciari R, Costantino G, Marinozzi M, Macchiarulo A, Amori L, Josef Flor P, Gasparini F, Kuhn R, Urwyler S.

Bioorg Med Chem Lett. 2001 Dec 17;11(24):3179-82.

PMID:
11720869
43.

Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501.

Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hofstetter K, Froestl W, Bettler B, Kaupmann K.

Mol Pharmacol. 2001 Nov;60(5):963-71.

PMID:
11641424
45.

Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit.

Galvez T, Urwyler S, Prézeau L, Mosbacher J, Joly C, Malitschek B, Heid J, Brabet I, Froestl W, Bettler B, Kaupmann K, Pin JP.

Mol Pharmacol. 2000 Mar;57(3):419-26.

PMID:
10692480
46.

2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist.

Gasparini F, Lingenhöhl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Veliçelebi G, Kuhn R.

Neuropharmacology. 1999 Oct;38(10):1493-503.

PMID:
10530811
47.

(R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo.

Gasparini F, Bruno V, Battaglia G, Lukic S, Leonhardt T, Inderbitzin W, Laurie D, Sommer B, Varney MA, Hess SD, Johnson EC, Kuhn R, Urwyler S, Sauer D, Portet C, Schmutz M, Nicoletti F, Flor PJ.

J Pharmacol Exp Ther. 1999 Jun;289(3):1678-87.

PMID:
10336568
49.

Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo.

Urwyler S, Campbell E, Fricker G, Jenner P, Lemaire M, McAllister KH, Neijt HC, Park CK, Perkins M, Rudin M, Sauter A, Smith L, Wiederhold KH, Müller W.

Neuropharmacology. 1996 Jun;35(6):655-69.

PMID:
8887975

Supplemental Content

Loading ...
Support Center